Brenda Cristie Edina

Ms. Brenda Cristie Edina

University of Indonesia, Depok, Jawa Barat, Indonesia

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Research Journal of Pharmacy and Technology
Verified
Journal Article
Closed access
PDF file
LWLowilius Wiyono
Lowilius Wiyono
BEBrenda Cristie Edina
Brenda Cristie Edina
RRRisya Amelia Rahmawanti
Risya Amelia Rahmawanti
NANurma Nur Azizah
Nurma Nur Azizah
RPRafika Indah Paramita
Rafika Indah Paramita
DFDila Fadilah
Dila Fadilah
Breast cancer is the 3rd most common cancer in the world and the most common one in women. An alternative pharmacological treatment for breast cancer is needed. Kaempferia pandurata is an endemic plant in Asia which is known for its biological activity, of which is an anticancer activity with its most abundant bioactive compound, pinostrobin. The rhizome of Kaempferia pandurata is dried and extracted using maseration with n-Hexane solvent. The extract then isolated using the recrystallization method in methanol solvent to produce pinostrobin crystal. Pinostrobin is manufactured into nanoparticle using chitosan and sodium alginate polymer, which then analyzed using TEM and UV-Vis test. The pinostrobin and its nanoparticle counterpart are tested in MTT assay to show its inhibitory activity and then analyzed. TEM and UV-Vis test to the nanoparticle of pinostrobin showed the nanoparticle's dimension of <200 nm with a yield of 99.43%. MTT assay showed good anticancer activity from both pinostrobin and its nanoparticle. Better activity is shown by MDAMB-231 cell, while nanoparticle of pinostrobin showed better activity. The nanoparticle of pinostrobin has been manufactured with a decent yield and dimension. Better anticancer activity is shown in pinostrobin nanoparticle while the anticancer activity of MDAMB-231 cell is superior to MCF-7 cell for both samples. Pinostrobin can be considered as a potential drug for breast cancer.

1 January 2019 in Research Journal of Pharmacy and Technology
Verified
Journal Article
Closed access
DFDila Fadilah
Dila Fadilah
LWLowilius Wiyono
Lowilius Wiyono
BEBrenda Cristie Edina
Brenda Cristie Edina
RRRisya Amelia Rahmawati
Risya Amelia Rahmawati
LELinda Erlina
Linda Erlina
RPRafika Indah Paramita
Rafika Indah Paramita

19 July 2022 in Cancers
Verified
Journal Article
Open access
PDF file
IRIkhwan Rinaldi
Ikhwan Rinaldi
AMAbdul Muthalib
Abdul Muthalib
BEBrenda Cristie Edina
Brenda Cristie Edina
LWLowilius Wiyono
Lowilius Wiyono
KWKevin Winston
Kevin Winston
Over the past few decades, treatment options have become more advanced for multiple myeloma (MM), one of the most prevalent hematological cancers; however, multiple myeloma remains an incurable disease due to its poor response to therapy and high rates of resistance, which cause relapsed/refractory or multiple myeloma. Researchers have described anti-BCMA (B-cell maturation antigen) as a promising treatment regimen that targets the BCMA biomarker in the affected plasma cells. BCMA is a protein that is specifically expressed in plasma-cell neoplasms by using several mechanisms, such as CAR T cells (Chimeric Antigen Receptor T cells), antibody-drug conjugates, and bispecific T-cell engagers, thus allowing for a rapid response in the treatment of resistant or relapsed/refractory multiple myeloma patients. Anti-BCMA treatment is novel and specific in its mechanisms of action, with noninferior complete responses, higher overall survival rates, and fewer reported adverse events compared to other currently available treatment of MM. In this review, we compared anti-BCMA mechanisms with those of previously available therapies, such as those using immunomodulators and proteasome inhibitors, and discussed the advantages of using anti-BCMA as a potential first-line treatment for multiple myeloma patients.

Verified
Journal Article
Open access
PDF file
IRIkhwan Rinaldi
Ikhwan Rinaldi
IAihya fakhrurizal amin
ihya fakhrurizal amin
YSYuli Maulidiya Shufiyani
Yuli Maulidiya Shufiyani
IDIdham Rafly Dewantara
Idham Rafly Dewantara
BEBrenda Cristie Edina
Brenda Cristie Edina
YNYusuf Aji Samudera Nurrobi
Yusuf Aji Samudera Nurrobi
Venous thromboembolism (VTE) is a serious complication that can occur during and after postoperative treatment, including in treatment after orthopedic surgery. The current guidelines for VTE prophylaxis in postoperative patients recommend the use of LMWHs, one of which is enoxaparin. Another recommendation for use in pharmacological VTE prophylaxis is rivaroxaban, which has better efficacy than enoxaparin but a higher bleeding risk. The aim of this systematic review is to provide an update on the profile of rivaroxaban for VTE prophylaxis after orthopedic surgery. PubMed, SCOPUS, EMBASE, and EBSCOhost were searched up until May 2022. The outcome sought was efficacy and safety, described by the incidence of VTE and incidence of bleeding, respectively. Five randomized controlled trials (RCT) were finally included. Rivaroxaban was confirmed to have better efficacy by significantly reducing the risk of VTE and all-cause mortality (RR = 0.38; 95% CI = 0.27–0.54) compared to enoxaparin. However, regarding the safety variable, no significant difference was found between the incidence of major bleeding in rivaroxaban and enoxaparin (RR = 0.97; 95% CI = 0.56–1.68). The results of the analysis show that rivaroxaban has better efficacy than enoxaparin but the same safety profile, so when used, the bleeding of patients should still be monitored.

Verified
Journal Article
Open access
PDF file
IRIkhwan Rinaldi
Ikhwan Rinaldi
MYMira Yulianti
Mira Yulianti
EYEvy Yunihastuti
Evy Yunihastuti
WRWulyo Rajabto
Wulyo Rajabto
CICosphiadi Irawan
Cosphiadi Irawan
BEBrenda Cristie Edina
Brenda Cristie Edina
Introduction: Indonesia, as a developing country, has limited data on the factors associated with 30-day mortality in COVID-19 patients in Indonesia. As a matter of fact, study analyzing factors associated with 30-day mortality of COVID-19 infection in Indonesia has never been conducted. This study aims to fill this gap in the literature by conducting a large-scale analysis of factors associated with 30-day mortality in COVID-19 patients in Indonesia. Method: This study employed a single-center retrospective cohort observational design, and was conducted at Cipto Mangunkusumo National General Hospital between the years 2022 and 2023. Sampling was conducted using the consecutive sampling method. The study included patients aged 18 years and above who had been confirmed to have COVID-19 infection. Survival analysis was conducted using Kaplan–Meier and multivariate Cox regression analysis. Result: Our study included a total of 644 patients, with 120 patients (18.6%) expiring within 30 days. In the multivariate analysis using the backward Wald method, severe COVID-19 (HR: 7.024; 95% CI: 3.971–12.744; p value: <0.0001), moderate COVID-19 infection (HR: 1.660; 95% CI: 1.048–2.629; p value: 0.031), liver cirrhosis (HR: 3.422; 95% CI: 1.208–9.691; p value: 0.021), female sex (HR: 1.738; 95% CI: 1.187–2.545; p value: 0.004), old age (HR: 2.139; 95% CI: 1.279–3.577; p value: 0.004), high leukocyte (HR: 11.502; 95% CI: 1.523–86.874; p value: 0.018), high NLR (HR: 1.720; 95% CI: 1.049–2.819; p value: 0.032), high CRP (HR: 1.906; 95% CI: 1.092–3.329; p value: 0.023), high procalcitonin (HR: 3.281; 95% CI: 1.780–6.049; p value: 0.001), and high creatinine (HR: 1.863; 95% CI: 1.240–2.800; p value: 0.003) were associated with 30-day mortality from COVID-19 infection. Subgroup analysis excluding cancer patients showed that age, D-Dimer, CRP, and PCT were associated with 30-day mortality in COVID-19 patients, while steroid therapy is protective. Conclusions: This study finds that COVID-19 severity, liver cirrhosis, sex, age, leukocyte, NLR, CRP, creatinine, and procalcitonin were associated with COVID-19 mortality within 30 days. These findings underscore the multifactorial nature of COVID-19 infection mortality. It is important, therefore, that patients which exhibit these factors should be treated more aggressively to prevent mortality.

10 February 2020 in Pharmacognosy Journal
Verified
Journal Article
Open access
PDF file
RRRisya Amelia Rahmawanti
Risya Amelia Rahmawanti
DFDila Fadilah
Dila Fadilah
BEBrenda Cristie Edina
Brenda Cristie Edina
LWLowilius Wiyono
Lowilius Wiyono
RPRafika Indah Paramita
Rafika Indah Paramita
This study is an experimental study and conducted at Department of Medical Chemistry-Faculty of Medicine University of Indonesia at Januari to April 2019. The free variables in this study are K. pandurata Roxb n-hexane extract and nanoparticle, the bound variable is MDA-MB-231 breast cancer cell, and the confounding variables are temperature and pH. K. pandurata Roxb. preparation Kaempferia pandurata Roxb. was used in this study was obtained from Banjarnegara, West Java. MDA-MB-231 cell lines where obtained from Biobank Research FKUI-RSCM. The cell was supplemented with 10% fetal bovine serum (FBS) and incubated at 37 o C with 4% CO 2. The viability of the cell is determined with trypan blue 0,1%.